Open AccessCalreticulin synthetic peptide analogues: anti‐peptide antibodies in autoimmune rheumatic diseases
Author(s) -
ROUTSIAS J. G.,
TZIOUFAS A. G.,
SAKARELLOSDAITSIOTIS M.,
SAKARELLOS C.,
MOUTSOPOULOS H. M.
Publication year - 1993
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1993.tb05921.x
Subject(s) - calreticulin , autoantibody , immunology , mixed connective tissue disease , antibody , peptide , rheumatoid arthritis , autoimmune disease , autoimmunity , medicine , antigen , recombinant dna , peptide sequence , biology , biochemistry , endoplasmic reticulum , gene
SUMMARY Autoantibodies in sera from patients with systemic lupus erythemalosus (SLE) and onchocerciasis recognize calreticulin (CaR). a calcium‐binding protein, as antigen. In this study we present the immunological properties of two synthetic peptides prepared to correspond to the 1–24 and 7–24 amino acid sequence of CaR. In contrast to information previously reported for the recombinant protein, the CaR‐peptide analogues appeared immunoreactive to anti‐Ro/SSA autoimmune sera. Human sera from patients with SLE, Sjogren's syndrome (SS), rheumatoid arthritis (RA), as well as mixed connective tissue disease (MCTD), demonstrated a positive autoimmune response (binding of antibodies), to the CaR‐peptide analogues. These findings suggest that anti‐calreticulin autoantibodies are not restricted to any disease specificity.